pds0101
Generic: Versamune® HPV·Code: PDS0101
pds0101: developed by 1 company · 1 clinical trial tracked.
pds0101 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect pds0101 to PDSB; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could pds0101 → PDSB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
HPV16-positive first-line treatment of recurrent/metastatic head and neck squamous cell carcinomaAnal CancerCervical CancerHIV (Human Immunodeficiency Virus)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PDS Biotechnology Corp (PDSB) HPV16-positive first-line treatment of recurrent/metastatic … | Phase 3 |
Clinical Trials (1)
CASCADE: A Single-Arm, Open-Label Clinical Phase II Trial of the Safety and Immunogenicity of PDS0101 in People Living With HIV
Primary endpoint: Safety: Number of Grade 3 or greater adverse events (AE) at least possibly related to PDS0101.
Interventionalopen0 enrolledStarted 2026-04Completion 2026-123 sites · Puerto Rico, United StatesUniversity of California, San Diego
Frequently asked questions
Who is developing pds0101?
pds0101 is being developed by PDS Biotechnology Corp.
How many clinical trials involve pds0101?
BioSniper tracks 1 clinical trial involving pds0101.